The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1125-1134

  Rao, V Ashutosh ^a   Zhang, Jun ^a   Klein, Sarah R ^a   Espandiari, Parvaneh ^a   Knapton, Alan ^a   Dickey, Jennifer S ^a   Herman, Eugene ^a   Shacter, Emily B ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Anthracyclines; Cardiotoxicity; Dexrazoxane; Dp44mT; Spontaneously hypertensive rats

Indexed keywords

DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DOXORUBICIN; IRON CHELATING AGENT; RAZOXANE; TROPONIN T; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CARDIOTOXICITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG INDICATION; DRUG MECHANISM; DRUG TREATMENT FAILURE; ESSENTIAL HYPERTENSION; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TISSUE INJURY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; HEART; HUMANS; IMMUNOHISTOCHEMISTRY; IRON CHELATING AGENTS; MALE; RATS; RATS, INBRED SHR; THIOSEMICARBAZONES; TROPONIN T;

EID: 82455175282     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1587-y     Document Type: Article

References (30)

1. E Barry JA Alvarez RE Scully TL Miller SE Lipshultz 2007 Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management Expert Opin Pharmacother 8 1039 1058 17516870 10.1517/14656566.8.8. 1039 1:CAS:528:DC%2BD2sXls1agsbc%3D (Pubitemid 46929299)
2. R Bolli 2001 Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research J Mol Cell Cardiol 33 1897 1918 11708836 10.1006/jmcc.2001.1462 1:CAS:528:DC%2BD3MXot12gs7k%3D (Pubitemid 33097270)
3. WM Bonner CE Redon JS Dickey AJ Nakamura OA Sedelnikova S Solier Y Pommier 2008 gammaH2AX and cancer Nat Rev Cancer 8 957 967 19005492 10.1038/nrc2523 1:CAS:528:DC%2BD1cXhsVWhu7rK
4. JS Dickey BJ Baird CE Redon MV Sokolov OA Sedelnikova WM Bonner 2009 Intercellular communication of cellular stress monitored by gamma-H2AX induction Carcinogenesis 30 1686 1695 19651821 10.1093/carcin/bgp192 1:CAS:528: DC%2BD1MXht1GmtrvK
5. BB Hasinoff D Patel 2009 The iron chelator Dp44mT does not protect myocytes against doxorubicin J Inorg Biochem 103 1093 1101 19535146 10.1016/j.jinorgbio.2009.05.007 1:CAS:528:DC%2BD1MXnvVWlt7g%3D
6. EH Herman J Zhang DP Chadwick VJ Ferrans 2000 Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats Cancer Chemother Pharmacol 45 329 334 10755322 10.1007/s002800050048 1:CAS:528:DC%2BD3cXhtlCrtbw%3D (Pubitemid 30151527)
7. J Hescheler R Meyer S Plant D Krautwurst W Rosenthal G Schultz 1991 Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart Circ Res 69 1476 1486 1683272 1:CAS:528:DyaK38Xht1ChtLg%3D
8. EM Hoke CA Maylock E Shacter 2005 Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin Free Radic Biol Med 39 403 411 15993339 10.1016/j.freeradbiomed.2005.03.029 1:CAS:528:DC%2BD2MXlvVWks7w%3D (Pubitemid 40910197)
9. AR Imondi 1998 Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects Semin Oncol 25 22 30 9768820 1:CAS:528:DyaK1cXmvFWgt7w%3D (Pubitemid 28460380)
10. H Kaiserova GJ den Hartog T Simunek L Schroterova E Kvasnickova A Bast 2006 Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin Br J Pharmacol 149 920 930 17031387 10.1038/sj.bjp.0706930 1:CAS:528:DC%2BD28Xht1ClsrjF (Pubitemid 44851716)
11. B Kalyanaraman J Joseph S Kalivendi S Wang E Konorev S Kotamraju 2002 Doxorubicin-induced apoptosis: implications in cardiotoxicity Mol Cell Biochem 234-235 119 124 12162424 10.1023/A:1015976430790 (Pubitemid 34777848)
12. RS Khan K Drosatos IJ Goldberg 2010 Creating and curing fatty hearts Curr Opin Clin Nutr Metab Care 13 145 149 20010095 10.1097/MCO.0b013e3283357272
13. YL Lyu JE Kerrigan CP Lin AM Azarova YC Tsai Y Ban LF Liu 2007 Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane Cancer Res 67 8839 8846 17875725 10.1158/0008-5472.CAN-07-1649 1:CAS:528:DC%2BD2sXhtVCit7jK (Pubitemid 47437460)
14. AK McClendon N Osheroff 2007 DNA topoisomerase II, genotoxicity, and cancer Mutat Res 623 83 97 17681352 10.1016/j.mrfmmm.2007.06.009 1:CAS:528:DC%2BD2sXhtVWmsbzF (Pubitemid 47368578)
15. G Minotti P Menna E Salvatorelli G Cairo L Gianni 2004 Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 185 229 15169927 10.1124/pr.56.2.6 1:CAS:528:DC%2BD2cXltlKgtb0%3D (Pubitemid 38720829)
16. MS Mitra S Donthamsetty B White HM Mehendale 2008 High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity Toxicol Appl Pharmacol 231 413 422 18674790 10.1016/j.taap.2008.05.006 1:CAS:528: DC%2BD1cXhtVylurbJ
17. C Myers 1998 The role of iron in doxorubicin-induced cardiomyopathy Semin Oncol 25 10 14 9768818 1:CAS:528:DyaK1cXmvFWgtrY%3D (Pubitemid 28460378)
18. Y Qiu A Rizvi XL Tang S Manchikalapudi H Takano AK Jadoon WJ Wu R Bolli 1997 Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits Am J Physiol 273 H2931 H2936 9435634 1:CAS:528: DyaK1cXjsVyntg%3D%3D
19. VA Rao AM Fan L Meng CF Doe PS North ID Hickson Y Pommier 2005 Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage Mol Cell Biol 25 8925 8937 16199871 10.1128/MCB.25.20.8925-8937.2005 1:CAS:528:DC%2BD2MXhtFWis77P (Pubitemid 41429083)
20. VA Rao SR Klein KK Agama E Toyoda N Adachi Y Pommier EB Shacter 2009 The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells Cancer Res 69 948 957 19176392 10.1158/0008-5472.CAN-08-1437 1:CAS:528:DC%2BD1MXhtFOktbc%3D
21. Richardson DR, Lane DJ, Becker EM, Huang ML, Whitnall M, Rahmanto YS, Sheftel AD, Ponka P (2010) Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci USA 107:10775-10782
22. EP Rogakou C Boon C Redon WM Bonner 1999 Megabase chromatin domains involved in DNA double-strand breaks in vivo J Cell Biol 146 905 916 10477747 10.1083/jcb.146.5.905 1:CAS:528:DyaK1MXlvVKjsbw%3D (Pubitemid 29430435)
23. VA Sardao PJ Oliveira J Holy CR Oliveira KB Wallace 2009 Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts Cancer Chemother Pharmacol 64 811 827 19184017 10.1007/s00280-009-0932-x 1:CAS:528:DC%2BD1MXptFCksL8%3D
24. P Skehan R Storeng D Scudiero A Monks J McMahon D Vistica JT Warren H Bokesch S Kenney MR Boyd 1990 New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1107 1112 2359136 10.1093/jnci/82.13.1107 1:CAS:528:DyaK3cXltVylsL8%3D (Pubitemid 20213250)
25. E Tatlidede O Sehirli A Velioglu-Ogunc S Cetinel BC Yegen A Yarat S Suleymanoglu G Sener 2009 Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage Free Radic Res 43 195 205 19169920 10.1080/10715760802673008 1:CAS:528:DC%2BD1MXjtVyht7g%3D
26. KB Wallace E Hausner E Herman GD Holt JT MacGregor AL Metz E Murphy IY Rosenblum FD Sistare MJ York 2004 Serum troponins as biomarkers of drug-induced cardiac toxicity Toxicol Pathol 32 106 121 14713555 10.1080/01926230490261302 1:CAS:528:DC%2BD2cXhs1Cntw%3D%3D (Pubitemid 38249998)
27. M Whitnall J Howard P Ponka DR Richardson 2006 A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics Proc Natl Acad Sci USA 103 14901 14906 17003122 10.1073/pnas.0604979103 1:CAS:528:DC%2BD28XhtVyhu7jL (Pubitemid 44527826)
28. KY Wonders DS Hydock S Greufe CM Schneider R Hayward 2009 Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974 Cancer Chemother Pharmacol 64 1105 1113 19352663 10.1007/s00280-009-0967-z 1:CAS:528:DC%2BD1MXhtVWhsrjM
29. Yan T, Deng S, Metzger A, Godtel-Armbrust U, Porter AC, Wojnowski L (2009) Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Mol Cancer Ther 8(5):1075-1085
30. J Yuan DB Lovejoy DR Richardson 2004 Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment Blood 104 1450 1458 15150082 10.1182/blood-2004-03-0868 1:CAS:528:DC%2BD2cXnt1ers74%3D (Pubitemid 39166524)